Monday, September 17, 2012

3 Reasons You Can't Miss Partnering for Cures

  1. It's all about solutions. This meeting is designed to get things done - from dynamic panel discussions about transformative ideas and successful models, to the dozens of case study presentations about innovative paths toward meeting R&D goals.
  2. It's all about collaboration. No other meeting of this scale is solely dedicated to forging strategic cross-sector collaborations. You will learn about innovative partnerships that are paving the path toward a more effective and efficient R&D system, and find partners who could make a meaningful difference.
  3. It's YOUR meeting. Whether you're looking for an investor or a scientific partner, a customized partnering system allows you to easily connect with potential allies from all sectors of medical research. Experts will be available on-site for one-on-one, free consultation sessions to help address your challenges. It is a unique opportunity to get a pulse on trends and best practices that matter to you and what you do.

Look who's speaking:

Francis Collins
Director, National Institutes of Health

Janet Woodcock
Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

William Chin
Executive Dean for Research, Harvard Medical School

Frank L. Douglas
President and CEO, Austen BioInnovation Institute

Regis B. Kelly
Director, The California Institute for Quantitative Biosciences, University of California

Stelios Papadopoulos
Co-Founder and Chairman, Exelixis

Kim J. Popovits
President and CEO, Genomic Health, Inc.

Jay Schnitzer
Director, Defense Sciences Office, Defense Advanced Research Projects Agency

Scott Johnson
President, CEO and Founder, Myelin Repair Foundation

Todd Sherer
CEO, Michael J. Fox Foundation

... and many more

Learn more about Partnering for Cures

Join >800 forward-thinking leaders:

Biotech and Pharma Senior Executives
  • Business Development Teams
  • Advocacy and Alliance Leaders
  • Federal Affairs Directors

Academic Medical Center Leaders
  • Research Hospital Executives
  • Institute Directors
  • Principal Investigators

Life Science Investors
  • Venture Capitalists
  • Medical Philanthropists
  • Wealth Advisors

Medical Research Innovators
  • Patient Advocates
  • Disease Foundation Executives
  • Venture Philanthropists

Government Decision Makers
  • Federal Funders
  • Federal Researchers and Regulators
  • Research Policy Makers
... and many more

No comments: